Otsuka Pharmaceutical Co., Ltd.'s Samsca® Approved In Japan As The World's First Drug Therapy For ADPKD, A Rare Kidney Disease

TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Samsca® (generic name: tolvaptan) has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of ADPKD. Also, the new dosage form of 30-mg Samsca tablets has received approval for the indication of ADPKD.

Help employers find you! Check out all the jobs and post your resume.